ABSTRACT
RATIONALE: Current recommendations for the treatment of rifampin- and multidrug-resistant tuberculosis include bedaquiline used for six months or longer. Evidence is needed to inform the optimal duration of bedaquiline.
OBJECTIVES: We emulated a target trial to estimate the effect of three bedaquiline duration treatment strategies (6 months, 7-11 months, ≥ 12 months) on the probability of successful treatment among patients receiving a longer individualized regimen for multidrug-resistant tuberculosis.
Find for download the pre-print of the endTB results manuscript (PDF format).
More information on the endTB clinical trial results page.
You can download the PowerPoint slides of our endTB trial results presentations at the Union World Conference, 15-18 November 2023.
More details on the endTB clinical trial results at this link: https://endtb.org/endtb-clinical-trial-results
Background: Treatment for fluoroquinolone-resistant multidrug-resistant/rifampicin-resistant tuberculosis (pre-XDR TB) often lasts longer than treatment for less resistant strains, yields worse efficacy results, and causes substantial toxicity. The newer anti-tuberculosis drugs, bedaquiline and delamanid, and repurposed drugs clofazimine and linezolid, show great promise for combination in shorter, less-toxic, and effective regimens.
More than six years ago, the endTB clinical trial was launched to find shorter, more tolerable, injection-free treatments for people with MDR-TB. Join us at the Union World Conference 2023 in Paris for the endTB clinical trial results presentation!
You can download our flyer on the endTB trial results presentations at the Union World Conference, 15-18 November 2023
